Live Updates > Live Update Details
2025-09-12 16:38:37
[Sinopharm Modern: New specifications of sodium bicarbonate injection have passed the evaluation] ⑴ Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. received the "Notice of Approval of Drug Supplementary Application" approved and issued by the State Food and Drug Administration, approving the increase in specifications of sodium bicarbonate injection and passing the generic drug quality and efficacy consistency evaluation. ⑵ Sodium bicarbonate injection is an antacid, and its indications include the treatment of metabolic acidosis, prevention of uric acid kidney stones, etc. The sales volume of public medical institutions nationwide in 2024 is approximately 580 million yuan. ⑶ Currently, other companies that have passed the consistency evaluation include Hefei Yuanfengshun Pharmaceutical Technology Co., Ltd., etc., and Sinopharm Rongsheng's cumulative R&D investment is approximately 2.7442 million yuan. ⑷ The company stated that the incident will be beneficial to the future market expansion and sales of the product, but will have no significant impact on the company's current performance.
